VX 828
Alternative Names: VX-828Latest Information Update: 11 Jan 2024
At a glance
- Originator Vertex Pharmaceuticals
- Class Antifibrotics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Cystic fibrosis
Most Recent Events
- 13 Dec 2023 Preclinical trials in Cystic fibrosis in USA (PO) (NCT06154447)
- 12 Dec 2023 Phase-I clinical trials in Cystic fibrosis (In adults, In volunteers) in USA (PO) (NCT06154447)
- 04 Dec 2023 Vertex Pharmaceuticals plans a phase I trial for Cystic Fibrosis in unknown location (PO) in December 2023 (NCT06154447)